Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Operating Leases (2021 - 2025)

Historic Operating Leases for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $9.3 million.

  • Krystal Biotech's Operating Leases rose 5451.69% to $9.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.3 million, marking a year-over-year increase of 5451.69%. This contributed to the annual value of $9.3 million for FY2025, which is 5451.69% up from last year.
  • Latest data reveals that Krystal Biotech reported Operating Leases of $9.3 million as of Q4 2025, which was up 5451.69% from $9.5 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Operating Leases registered a high of $9.7 million during Q2 2025, and its lowest value of $3.9 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Leases was $8.4 million (2023), whereas its average is $8.2 million.
  • Per our database at Business Quant, Krystal Biotech's Operating Leases skyrocketed by 14015.5% in 2022 and then crashed by 2589.28% in 2023.
  • Krystal Biotech's Operating Leases (Quarter) stood at $8.0 million in 2021, then grew by 11.33% to $8.9 million in 2022, then decreased by 25.89% to $6.6 million in 2023, then fell by 8.7% to $6.0 million in 2024, then skyrocketed by 54.52% to $9.3 million in 2025.
  • Its Operating Leases was $9.3 million in Q4 2025, compared to $9.5 million in Q3 2025 and $9.7 million in Q2 2025.